Stryker Corporation

New York Stock Exchange
Back to all articles
Bullish +65

Stryker reports second quarter 2026 operating results

📈 Consolidated net sales increased 9.4% year-over-year to $6.6 billion, with organic growth of 9.0% driven by higher unit volumes.

💰 Reported net earnings surged 44.3% to $1.3 billion, while adjusted EPS rose 17.9% to $3.69 per diluted share.

📊 Operating income margin expanded to 25.2%, and adjusted operating income margin improved by 170 basis points to 27.4%.

🔬 MedSurg and Neurotechnology segment sales grew 9.7% to $3.6 billion, with organic growth of 9.2% including price increases.

🦴 Orthopaedics segment sales rose 9.1% to $3.0 billion, fueled by an 8.6% increase in organic unit volume.

📉 Stryker narrowed its full-year 2026 guidance, expecting organic net sales growth between 8.3% and 9.3%.

💵 Adjusted EPS guidance for the remainder of 2026 is set at $14.95 to $15.10, slightly below prior expectations.

🌍 Foreign currency exchange had a neutral impact on sales growth, with constant currency growth matching reported growth at 9.4%.

🛡️ CEO Kevin A. Lobo stated the company has regained momentum following recovery from the March 2026 cyber incident.

📅 The company will host an earnings conference call on July 30, 2026, at 4:30 p.m. Eastern Time to discuss results.

Bullish Signals
  • Consolidated net sales grew 9.4% year-over-year to $6.6 billion, significantly outpacing typical industry growth rates.
  • Organic net sales increased 9.0%, demonstrating strong underlying demand and successful product adoption without M&A contributions.
  • Adjusted EPS of $3.69 represents a 17.9% increase year-over-year, reflecting improved profitability and cost management.
  • Operating income margin expanded to 25.2%, indicating effective pricing power and operational efficiency improvements.
  • MedSurg and Neurotechnology segment delivered 9.7% sales growth with 9.2% organic expansion driven by unit volume and price.
  • Orthopaedics segment achieved 9.1% sales growth with 8.6% organic growth, primarily from increased unit volumes.
  • Gross profit margin reached 68.3%, showing strong cost control relative to revenue generation.
  • The company successfully recovered operational momentum following the cyber incident, restoring investor confidence in execution.
Risk Factors
  • Stryker narrowed its full-year 2026 guidance for organic net sales growth to 8.3%-9.3%, indicating a more cautious outlook than previously projected.
  • Regulatory and legal matters remain a risk factor, with charges included in reported earnings that could impact future margins if not managed effectively.
  • Foreign exchange rates are expected to have only a slightly favorable impact on sales and earnings, limiting potential upside from currency fluctuations.
Full Analysis
Stryker Corporation (NYSE:SYK) reported strong second-quarter 2026 operating results with consolidated net sales rising 9.4% to $6.6 billion, driven by organic growth across its MedSurg and Neurotechnology segments. The company highlighted a resilient recovery from a previously reported cyber incident, citing regained momentum in sales, earnings per share, and operating cash flow. CEO Kevin A. Lobo emphasized the team's resilience and disciplined operational execution as key factors in delivering these results. Financial performance was robust with reported net earnings increasing 44.3% to $1.3 billion and adjusted EPS rising 17.9% to $3.69. Operating income margin expanded significantly to 25.2%, while adjusted operating income margin improved by 170 basis points to 27.4%. Growth was consistent across major business lines, with MedSurg and Neurotechnology sales up 9.7% and Orthopaedics sales up 9.1%, both reflecting strong unit volume increases. Looking ahead, Stryker narrowed its full-year 2026 guidance for organic net sales growth to a range of 8.3% to 9.3% and adjusted EPS to $14.95 to $15.10. The company noted that this guidance includes a modestly positive pricing impact and expects slightly favorable foreign exchange effects if rates remain stable. Management expressed confidence in growing at the high end of its MedTech targets despite the narrowed outlook.